Century Therapeutics, Inc. (IPSC)
NASDAQ: IPSC · Real-Time Price · USD
0.5055
-0.0048 (-0.94%)
Sep 9, 2025, 12:30 PM - Market open

Company Description

Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases.

Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma.

The company is also involved in the development of CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 demonstrating preclinical efficacy comparable to autologous CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases and malignancies; and CNTY-341, A CD19/CD22 dual-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 which pairs dual targeting and primary T-cell-like functionality in an allogeneic cell with the goal of providing a differentiated therapy for B cell malignancies that are in preclinical trial.

In addition, it develops solid tumor CAR iT program exploiting Nectin-4 CAR and other validated targets, engineered with Allo-Evasion 5.0 and additional engineering aimed at overcoming the key barriers to success in solid tumors, as well as non-immune effector.

The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Century Therapeutics, Inc.
Century Therapeutics logo
CountryUnited States
Founded2019
IPO DateJun 18, 2021
IndustryBiotechnology
SectorHealthcare
Employees150
CEOBrent Pfeiffenberger

Contact Details

Address:
25 North 38th Street, 11th Floor
Philadelphia, Pennsylvania 19104
United States
Phone267 817 5790
Websitecenturytx.com

Stock Details

Ticker SymbolIPSC
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$20.00
CIK Code0001850119
CUSIP Number15673T100
ISIN NumberUS15673T1007
Employer ID84-2040295
SIC Code2836

Key Executives

NamePosition
Dr. Brent Pfeiffenberger M.B.A., Pharm.D.President, Chief Executive Officer and Chairman
Dr. Gregory Russotti Ph.D.Chief Technology and Manufacturing Officer
Douglas Carr CPAPrincipal Financial Officer and Secretary
Dr. Chad A. Cowan Ph.D.Chief Scientific Officer
Michael Naso Ph.D.Senior Vice President of Cell Engineering
Elizabeth DevlinVice President and Head of Development

Latest SEC Filings

DateTypeTitle
Sep 8, 2025144Filing
Sep 8, 2025144Filing
Aug 29, 20258-KCurrent Report
Aug 18, 2025144Filing
Aug 14, 202510-QQuarterly Report
Aug 14, 20258-KCurrent Report
Jul 10, 2025S-3Registration statement under Securities Act of 1933
Jul 7, 20258-KCurrent Report
Jun 16, 20258-KCurrent Report
Jun 9, 2025144Filing